Display options
Cite
Hassanzadeh P, Arbabi E. The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells. Iran J Basic Med Sci. 2012;15(5):1046-52
Hassanzadeh, P., & Arbabi, E. (2012). The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells. Iranian journal of basic medical sciences, 15(5), 1046-52.
Hassanzadeh, Parichehr, and Arbabi, Elham. "The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells." Iranian journal of basic medical sciences vol. 15,5 (2012): 1046-52.
Hassanzadeh P, Arbabi E. The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells. Iran J Basic Med Sci. 2012 Sep;15(5):1046-52. PMID: 23493386; PMCID: PMC3586917.
Copy Download .nbib Format: NLM
Share it on

Iran J Basic Med Sci. 2012 Sep;15(5):1046-52.

The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells.

Iranian journal of basic medical sciences

Parichehr Hassanzadeh, Elham Arbabi

Affiliations

  1. Research Centre for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

PMID: 23493386 PMCID: PMC3586917

Abstract

OBJECTIVES: Progesterone is a steroid hormone whose biology has been greatly studied within the confines of reproductive function. In recent years, the neuroprotective effects of progesterone have attracted growing interest. Glial cell line-derived neurotrophic factor (GDNF), is a neurotrophic factor which plays a crucial role in the development and maintenance of distinct sets of central and peripheral neurons. In the present study, we investigated the potential implication of GDNF in the neuroprotective action of progesterone.

MATERIALS AND METHODS: Cultured rat C6 glioma cells were treated with progesterone (100 nm, 1 µM, and 10 µM) or its vehicle. After 24, 36, 48 and 72 hr, GDNF protein levels were measured in the cell-conditioned media and cell lysates using a GDNF ELISA kit. Cell numbers were determined by a cell-counting assay kit.

RESULTS: Forty-eight hr treatment with progesterone (10 µM) resulted in a significant elevation of GDNF secretion from C6 glioma cells that remained elevated up to 72 hr. The intracellular content of GDNF and cell numbers were not affected by progesterone treatment.

CONCLUSION: Stimulation of GDNF release from glial cells appears as a potential mechanism through which progesterone exerts its neuroprotective effects.

Keywords: C6 glioma cells; GDNF; Progesterone

References

  1. J Neurosci Res. 2003 Jan 1;71(1):127-31 - PubMed
  2. J Cell Biol. 1995 Jul;130(1):137-48 - PubMed
  3. Exp Neurol. 2004 Oct;189(2):404-12 - PubMed
  4. Exp Neurol. 2005 Jun;193(2):522-30 - PubMed
  5. Exp Neurol. 2006 Apr;198(2):469-78 - PubMed
  6. Nature. 1995 Jan 26;373(6512):335-9 - PubMed
  7. Drug News Perspect. 2002 Jun;15(5):290-298 - PubMed
  8. J Neurotrauma. 2006 Feb;23(2):181-92 - PubMed
  9. J Neurosci Res. 2007 Aug 15;85(11):2441-9 - PubMed
  10. Trends Neurosci. 2003 Oct;26(10):531-5 - PubMed
  11. Eur Neuropsychopharmacol. 2011 Dec;21(12):905-17 - PubMed
  12. Brain Res. 2005 Jul 5;1049(1):112-9 - PubMed
  13. Brain Res. 2009 Aug 11;1284:1-11 - PubMed
  14. J Neurotrauma. 2001 Sep;18(9):901-9 - PubMed
  15. Mol Reprod Dev. 1998 Aug;50(4):451-60 - PubMed
  16. Neurosci Lett. 2003 Jun 12;343(3):163-6 - PubMed
  17. Chem Biol Interact. 2009 Jan 15;177(1):65-70 - PubMed
  18. Brain Res Rev. 2008 Mar;57(2):386-97 - PubMed
  19. Brain. 2006 Feb;129(Pt 2):490-502 - PubMed
  20. Brain Res. 2005 Nov 16;1062(1-2):171-4 - PubMed
  21. Curr Opin Neurobiol. 2006 Feb;16(1):119-25 - PubMed
  22. Mol Psychiatry. 2000 May;5(3):293-300 - PubMed
  23. Front Neuroendocrinol. 2009 Jul;30(2):173-87 - PubMed
  24. J Neurosurg. 2000 May;92(5):848-52 - PubMed
  25. Int J Neurosci. 2009;119(10):1718-40 - PubMed
  26. Brain Res. 2002 Nov 1;954(1):11-20 - PubMed
  27. Psychopharmacology (Berl). 2011 May;215(1):129-41 - PubMed
  28. J Mol Neurosci. 2006;28(1):3-15 - PubMed
  29. Neuroscientist. 2009 Aug;15(4):324-32 - PubMed
  30. J Clin Endocrinol Metab. 2002 Nov;87(11):5325-31 - PubMed
  31. J Neurochem. 2000 Mar;74(3):1175-84 - PubMed
  32. Nature. 1996 Mar 21;380(6571):252-5 - PubMed
  33. Brain Res. 2006 Sep 21;1111(1):227-9 - PubMed
  34. J Cereb Blood Flow Metab. 2004 Jul;24(7):805-13 - PubMed
  35. Science. 1993 May 21;260(5111):1130-2 - PubMed
  36. Neurobiol Dis. 2002 Dec;11(3):457-68 - PubMed
  37. Neuroscience. 2004;123(2):349-59 - PubMed
  38. Nature. 1995 Jan 26;373(6512):344-6 - PubMed
  39. Trends Neurosci. 2001 Jul;24(7):386-91 - PubMed
  40. Learn Mem. 1999 May-Jun;6(3):193-215 - PubMed
  41. J Neurochem. 1998 Oct;71(4):1765-8 - PubMed
  42. J Neurosci Res. 2003 Jul 1;73(1):105-12 - PubMed
  43. J Neurochem. 2005 Jun;93(5):1314-26 - PubMed
  44. J Neurotrauma. 2005 Jan;22(1):106-18 - PubMed
  45. Endocrine. 2006 Apr;29(2):271-4 - PubMed
  46. Nat Rev Neurosci. 2001 Mar;2(3):185-93 - PubMed
  47. Restor Neurol Neurosci. 2007;25(2):151-9 - PubMed
  48. Neuropharmacology. 2005 Jan;48(1):14-24 - PubMed
  49. J Neurosci Res. 2006 Jan;83(1):50-60 - PubMed
  50. J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):143-9 - PubMed
  51. Neuroscience. 2005;136(1):161-9 - PubMed
  52. J Neuroendocrinol. 1995 Mar;7(3):171-7 - PubMed
  53. Neurosci Lett. 2002 Mar 15;321(1-2):65-8 - PubMed
  54. Mol Cell Biol. 2006 Apr;26(7):2746-57 - PubMed
  55. Neuroscience. 2007 Feb 23;144(4):1293-304 - PubMed
  56. Exp Neurol. 2003 Mar;180(1):32-45 - PubMed
  57. J Physiol Paris. 2006 Mar-May;99(2-3):84-91 - PubMed
  58. Ann Emerg Med. 2008 Feb;51(2):164-72 - PubMed
  59. J Neurochem. 2001 Oct;79(1):25-34 - PubMed
  60. Stroke. 2007 Jul;38(7):2165-72 - PubMed

Publication Types